Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo CAR-T Therapy for Relapsed or Refractory Hematologic Malignancies
NCT07239323Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBC027 in acute lymphoblastic leukemia (ALL), B-cell non-Hodgkin lymphoma and multiple myeloma (MM), sponsored by Chongqing Precision Biotech. Primary endpoints: Maximal Tolerated Dose at 28 days and Incidence of adverse events at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
PBC027
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT07239323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239323.